NCT05429502: A trial that was reported late by Novartis Pharmaceuticals
This trial was previously reported as an Applicable Clinical Trial, but is no longer.
Full data
| Full entry on ClinicalTrials.gov | NCT05429502 |
|---|---|
| Title | Phase I/II Multicenter Study to Assess Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors |
| Results Status | no-longer-act |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 27, 2022 |
| Completion date | Oct. 15, 2027 |
| Required reporting date | Oct. 14, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | June 11, 2025 |
| Days late | None |